Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations
Authors
Keywords
-
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 38, Issue S1, Pages E1838-E1847
Publisher
Wiley
Online
2015-12-24
DOI
10.1002/hed.24332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
- (2015) Jan Bogaerts et al. EUROPEAN JOURNAL OF CANCER
- AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants
- (2015) J. F. Hechtman et al. MOLECULAR CANCER RESEARCH
- Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
- (2014) Tatsuo Masubuchi et al. International Journal of Clinical Oncology
- High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
- (2014) Bo Mi Ku et al. Journal of Translational Medicine
- OncogenicPIK3CAMutation and Dysregulation in Human Salivary Duct Carcinoma
- (2014) Wanglong Qiu et al. Biomed Research International
- PIK3CA Mutations and PTEN Loss in Salivary Duct Carcinomas
- (2013) Christopher C. Griffith et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma
- (2013) Po Yee Yip et al. Journal of Thoracic Oncology
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab for the Treatment of Salivary Duct Carcinoma
- (2013) S. A. Limaye et al. ONCOLOGIST
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
- (2012) Georgina V. Long et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
- (2012) V. Nardi et al. CLINICAL CANCER RESEARCH
- PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients
- (2012) FR Mangone et al. Clinics
- Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes*
- (2012) Silvana Di Palma et al. HISTOPATHOLOGY
- Salivary duct carcinoma: what is already known, and can we improve survival?
- (2012) D T H Wee et al. JOURNAL OF LARYNGOLOGY AND OTOLOGY
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options
- (2011) Heidy C.J. Jaspers et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland
- (2008) Hidetaka Yamamoto et al. PATHOLOGY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started